EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Role of Vimentin 3 in Ameloblastomas: A Novel Tumor Biomarker

Sibel Elif Gultekin iD, Melanie von Brandenstein iD, Emre Baris iD, Ipek Atak Secen iD, Leyla Arslan Bozdag iD, Heike Goebel iD

Oral Diseases · 2025

DOI: 10.1111/odi.15396 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oral Diseases, 2025. Verfasst von Sibel Elif Gultekin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Pathology, Faculty of Dentistry, Gazi University, Ankara, Turkey. Hauptthemen laut MEDLINE: Ameloblastoma, Biomarkers, Tumor, Vimentin, Jaw Neoplasms. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Marga and Walter Boll Stiftung, Kerpen, Germany, The Scientific and Technological Research Council of Turkey (TUBITAK) - Deutscher Akademischer Austauschdienst (DAAD) - Bilateral Cooperation Funding Program.…, Türkiye Bilimsel ve Teknolojik Araştırma Kurumu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Ameloblastoma (ABL), a common odontogenic tumor in the maxillofacial region, presents primarily as unicystic (U‐ABL) and conventional (C‐ABL) variants. Despite shared epithelial features, their distinct biological behaviors may stem from interactions between connective tissue and epithelial cells. Vimentin 3 (VIM3), a truncated variant of Vimentin‐Full Length (VIMFL), exhibits unique biological properties. This study is the first to investigate VIM3 expression in ABLs.

Methods

Formalin‐fixed paraffin‐embedded (FFPE) samples of C‐ABL ( n = 30), U‐ABL ( n = 30), and dental follicles (DF, n = 30) were analyzed. Immunohistochemical evaluation of VIM3, VIMFL, WNT5a, and MTCO1 was performed, alongside qRT‐PCR for VIM3, VIMFL, WNT5a, ROR2, and miR‐498.

Results

VIM3 expression was significantly higher in C‐ABL ( p < 0.0001) compared to U‐ABL and DFs. VIMFL was absent in the epithelial components of all cases. C‐ABL showed significantly higher WNT5a ( p < 0.0001) and MTCO1 ( p = 0.0327) expression. qRT‐PCR revealed significant differences in VIM3 and miR‐498 levels between U‐ABL and DFs ( p < 0.0001). No significant differences were found for WNT5a, VIMFL, or ROR2 ( p > 0.05).

Conclusion

This study identifies VIM3 expression in ABLs, distinct from VIMFL, suggesting its potential as a biomarker. Additionally, mitochondrial dysfunction may play a role in ABL tumorigenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmeloblastomaBiomarkers, TumorVimentinJaw NeoplasmsHumansWnt-5a ProteinMicroRNAsMaleFemaleReceptor Tyrosine Kinase-like Orphan ReceptorsAdultMiddle AgedDental SacImmunohistochemistryAdolescent

Stichwörter der Autor:innen

ameloblastomaodontogenic tumorvimentin 3

Substanzen

Wnt-5a ProteinBiomarkers, TumorVimentinMicroRNAsWNT5A protein, humanReceptor Tyrosine Kinase-like Orphan ReceptorsROR2 protein, humanVIM protein, human

Autor:innen und Institutionen

  • Department of Oral Pathology, Faculty of Dentistry, Gazi University, Ankara, Turkey.
  • Clinic and Polyclinic for Urology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Institute of Pathology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

ORCID-Profile: Sibel Elif Gultekin, Melanie von Brandenstein, Emre Baris, Ipek Atak Secen, Leyla Arslan Bozdag, Heike Goebel

Förderung

  • Marga and Walter Boll Stiftung, Kerpen, Germany
  • The Scientific and Technological Research Council of Turkey (TUBITAK) - Deutscher Akademischer Austauschdienst (DAAD) - Bilateral Cooperation Funding Program.…
  • Türkiye Bilimsel ve Teknolojik Araştırma Kurumu

Zitieren

APA

Gultekin, S. E., von Brandenstein, M., Baris, E., Atak Secen, I., Arslan Bozdag, L., & Goebel, H. (2025). The Role of Vimentin 3 in Ameloblastomas: A Novel Tumor Biomarker. Oral Diseases. https://doi.org/10.1111/odi.15396

Vancouver

Gultekin SE, von Brandenstein M, Baris E, Atak Secen I, Arslan Bozdag L, Goebel H. The Role of Vimentin 3 in Ameloblastomas: A Novel Tumor Biomarker. Oral Diseases. 2025. doi:10.1111/odi.15396

BibTeX
@article{Gultekin2025,
  author = {Gultekin, Sibel Elif and von Brandenstein, Melanie and Baris, Emre and Atak Secen, Ipek and Arslan Bozdag, Leyla and Goebel, Heike},
  title = {The Role of Vimentin 3 in Ameloblastomas: A Novel Tumor Biomarker},
  journal = {Oral Diseases},
  year = {2025},
  doi = {10.1111/odi.15396}
}
Kostenlos starten →